SRZN vs. FATE, TCRX, INMB, RENB, KYTX, JMAC, MCRB, CRBU, SGMT, and VTYX
Should you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Fate Therapeutics (FATE), TScan Therapeutics (TCRX), INmune Bio (INMB), Renovaro (RENB), Kyverna Therapeutics (KYTX), Maxpro Capital Acquisition (JMAC), Seres Therapeutics (MCRB), Caribou Biosciences (CRBU), Sagimet Biosciences (SGMT), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry.
Surrozen vs.
Surrozen (NASDAQ:SRZN) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
Surrozen presently has a consensus target price of $45.00, suggesting a potential upside of 272.52%. Fate Therapeutics has a consensus target price of $6.75, suggesting a potential upside of 431.50%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Surrozen.
Surrozen has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat Surrozen's return on equity.
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 43.5% of Surrozen shares are owned by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Fate Therapeutics received 476 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 68.09% of users gave Fate Therapeutics an outperform vote while only 21.05% of users gave Surrozen an outperform vote.
Surrozen has higher earnings, but lower revenue than Fate Therapeutics.
In the previous week, Fate Therapeutics had 3 more articles in the media than Surrozen. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for Surrozen. Fate Therapeutics' average media sentiment score of 0.59 beat Surrozen's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.
Surrozen has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.
Summary
Fate Therapeutics beats Surrozen on 11 of the 16 factors compared between the two stocks.
Get Surrozen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surrozen Competitors List
Related Companies and Tools
This page (NASDAQ:SRZN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SRZN Stock Alerts